Navigation Links
3SBio Inc. Enters Into Merger Agreement For "Going Private" Transaction
Date:2/8/2013

SHENYANG, China, Feb. 8, 2013 /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has entered into an agreement and plan of merger (the "Merger Agreement") with Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("Parent"), and Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent ("Merger Sub").

Pursuant to the terms of the Merger Agreement, each of the Company's ordinary shares (a "Share"), including Shares represented by American Depositary Shares, each representing seven Shares (the "ADSs"), issued and outstanding immediately prior to the effective time of the merger will be cancelled in exchange for the right to receive US$2.20 in cash per Share, or US$15.40 per ADS, without interest, except for (i) the Shares beneficially owned by Parent, Merger Sub or certain Shares beneficially owned by certain directors, officers or employees of the Company (collectively, the "Rollover Shareholders"), and certain restricted shares and restricted share units issued by the Company to the Rollover Shareholders (collectively, the "Consortium Shares"), (ii) the Shares beneficially owned by the Company or any direct or indirect wholly owned Subsidiary of the Company and (iii) the Shares owned by holders who have validly exercised and not effectively withdrawn or lost their appraisal rights pursuant to Section 238 of the Cayman Islands Companies Law, as amended. The per Share consideration of US$2.20 or per ADS consideration of US$15.40
'/>"/>

SOURCE 3SBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. 3SBio Inc. to Present at the UBS Greater China Conference 2012
2. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2011
3. 3SBio Inc. Announces Unaudited First Quarter 2012 Results
4. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
5. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
6. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
7. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
8. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
9. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
10. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
11. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Oven Industries Inc. announces a new temperature ... has many user-friendly benefits. Contained all in one enclosure, ... a self-contained temperature control system, which has ... device unique, as well as highly convenient for users. ... universally, which allows the user to use the device ...
(Date:5/17/2013)... 2013 The new Public-Private Partnership (PPP) ... the association’s recent annual meeting drew praise from community ... Kroes, who called the action “a huge step forward ... to European innovation.” , The Board of Stakeholders voted ... Photonics PPP at its 29 April meeting in Brussels, ...
(Date:5/17/2013)... May 17, 2013  Yongye International, Inc. (NASDAQ: ... developer, manufacturer, and distributor of crop nutrient products in ... today announced that, on May 16, 2013, the special ... (the "Board of Directors") was provided a letter (the ... Kong ) Limited ("Abax") to Full Alliance International ...
(Date:5/17/2013)... Canada (PRWEB) May 17, 2013 The ... understanding complex biological systems that can help predict the ... speaker Dr. Sergey Stepaniants, Head of Computational Biology at ... computational biology tools to ensure high-quality genomics when used ... can be applied to complex data sets to identify ...
Breaking Biology Technology:New Temperature Control Products Announced by Oven Industries Inc. 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... Reportlinker.com announces that a new market research ... Future of White Biotechnology in ... White biotechnology (WB) industry, which ... in biotechnology, is one of the most ...
... (Nasdaq: TELK ) today announced the initiation of ... patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome ... intended to enroll up to 117 evaluable patients. It employs ... transfusion dependent with Low to Intermediate-1 Risk MDS. Telintra will ...
... YORK, June 7, 2011 DuPont (NYSE: ... told investors at the JPMorgan Diversified Industries Conference to ... process innovation, selective investment in attractive areas, broad-based growth, ... productivity.  Kullman also reaffirmed DuPont,s 2011 earnings per share ...
Cached Biology Technology:Reportlinker Adds Future of White Biotechnology in China 2Reportlinker Adds Future of White Biotechnology in China 3Reportlinker Adds Future of White Biotechnology in China 4Reportlinker Adds Future of White Biotechnology in China 5Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome 2Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome 3DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 2DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 3
(Date:5/16/2013)... at MIT may someday eliminate the need for ... their blood-sugar levels and inject themselves with insulin. ... levels in the body and respond by secreting ... function of pancreatic islet cells, which are destroyed ... type of system could ensure that blood-sugar levels ...
(Date:5/16/2013)... and athletes choose to wear the color red when ... Psychological Science , a journal of the Association ... do with their testosterone levels. , The new study, ... of Sunderland and colleagues, demonstrated that males who chose ... higher testosterone levels than other males who chose blue. ...
(Date:5/16/2013)... about 23 million years old give unprecedented insight ... one of the most species-rich groups among the ... Professor Bettina Reichenbacher from the Division of Paleontology ... Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich / ... fossils which they assign to the group of ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3High-testosterone competitors more likely to choose red 2Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
... University of British Columbia scientists have traced the fragrant ... the anthers, contrary to common perception that petals alone ... Cabernet Sauvignon from the Okanagan region of British Columbia, ... Laboratories identified a gene that produces and regulates fragrance ...
... Ponce de Leon combed the swamps of Florida seeking the ... Annual Meeting in New Orleans (held in conjunction with Experimental ... on the new molecular "fountain of youth," the genes and ... still be a long time away, the presentations at ASBMB ...
... Institute for Medical Research (Burnham) is pleased to announce ... papers on their data at the American Association for ... John C. Reed, M.D., Ph.D., Burnham President and CEO, ... panel on Apoptosis-based Strategies for Cancer Therapy, where he ...
Cached Biology News:ASBMB Annual Meeting to feature talks on the biochemistry of aging 2ASBMB Annual Meeting to feature talks on the biochemistry of aging 3
... Anti-AP-2 α, clone 8G8/5 GenBank Accession ... made human AP-2alpha/gamma fusion protein corresponding to ... 278-450 of human AP-2γ Formulation: 0.1M Tris-glycine, ... before the addition of glycerol to 30% ...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
... a glycoprotein. distributed in colon and ... breast, lung and salivary gland tissues. ... MUC1 and MUC2. Epitope: Tandem ... Immunogen: MUC3 tandem repeat peptide ...
Biology Products: